(Q38032176)

English

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents

scientific article published on 05 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

0 references

Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1 reference

based on heuristic

inferred from title

author name string

Jingwei Jiang

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Xiaohua Liang

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Xinli Zhou

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Ruofan Huang

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Zhaohui Chu

5

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Qiong Zhan

6

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

5 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

139

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

25-38

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

https://scigraph.springernature.com/pub.10.1007/s00432-012-1294-z

0 references

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1294-Z

21 January 2018

Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22864816

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-012-1294-Z

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38032176&oldid=1738076387"